Intellia Therapeutics prioritizes late-stage gene-editing programs for HAE and ATTR amyloidosis in 2025, announces leadership ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months.

Shares of Intellia Therapeutics, Inc. NTLA were down in pre-market trading on Jan. 10 after the company announced a strategic ...

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on the shares. The ...

DNA analysis of TTR gene to detect or exclude hereditary transthyretin-related amyloidosis (ATTR). - Serum free light chain assay to detect low grade plasma-cell dyscrasia. - Mass spectrometry for ...

About half of people who have transthyretin amyloid cardiomyopathy (ATTR-CM) experience an uncomfortable, nerve-related condition in the wrists called carpal tunnel syndrome. This link isn’t ...

Intellia Therapeutics (NASDAQ:NTLA) said it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z ...

These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.

Despite the market's response to the reorganization and workforce reduction, Intellia ended the fourth quarter of 2024 with a strong cash position of approximately $862 million. This financial ...